Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease.

Hematology. American Society of Hematology. Education Program - 8 Dec 2023

Abla Oussama

Abstract excerpt

Langerhans cell histiocytosis (LCH) is a rare myeloid neoplasm driven by activating mutations in the MAPK pathway, most commonly BRAF-V600E and MAP2K1. It affects children and adults, with a wide spectrum of clinical presentations ranging from self-limited to multisystem (MS) life-threatening forms. LCH is defined by the accumulation of CD1a+/CD207+ cells in different organs, and patients with liver, spleen, or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Central Nervous System Diseases
Share to Child
Share to Histiocytosis, Langerhans-Cell

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 38066856
DOI: 10.1182/hematology.2023000439
PMCID: PMC10726990

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease.PMID 38066856Read ↗

Clinical features and treatment of Langerhans cell histiocytosis.Semantic proximity Read ↗

Langerhans cell histiocytosis.Semantic proximity Read ↗

Clinical and prognostic features of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

Langerhans cell histiocytosis. Advances in pathogenesis and clinical practice.Semantic proximity Read ↗

Histiocyte Society blueprint for Langerhans cell histiocytosis research: from cell-of-origin to a more comprehensive cure.Semantic proximity Read ↗

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

Langerhans cell histiocytosis: current advances in molecular pathogenesis.Semantic proximity Read ↗

[Pathophysiology and treatment of adult Langerhans cell histiocytosis].Semantic proximity Read ↗

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Semantic proximity Read ↗

[Central nervous system disorders secondary to histiocytoses: neurodegeneration with potential for improvement].Semantic proximity Read ↗

Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosisSemantic proximity Read ↗

Langerhans cell histiocytosis: molecular mechanisms underlying pathogenesis and emerging targeted therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.